Rat Anti-Lrig1 Recombinant Antibody (CBYJL-2384) (CBMAB-L2695-YJ)

Moon, J. S., Ho, C. C., Park, J. H., Park, K., Shin, B. Y., Lee, S. H., ... & Lee, S. K. (2023). Lrig1-expression confers suppressive function to CD4+ cells and is essential for averting autoimmunity via the Smad2/3/Foxp3 axis. Nature Communications, 14(1), 5382.

Hopton, R. E., Jahahn, N. J., & Zemper, A. E. (2023). Lrig1 drives cryptogenesis and restrains proliferation during colon development. American Journal of Physiology-Gastrointestinal and Liver Physiology, 325(6), G570-G581.

Ji, Y., Kumar, R., Gokhale, A., Chao, H. P., Rycaj, K., Chen, X., ... & Tang, D. G. (2022, July). LRIG1, a regulator of stem cell quiescence and a pleiotropic feedback tumor suppressor. In Seminars in cancer biology (Vol. 82, pp. 120-133). Academic Press.

Umeh-Garcia, M., O’Geen, H., Simion, C., Gephart, M. H., Segal, D. J., & Sweeney, C. A. (2022). Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer. British journal of cancer, 127(3), 436-448.

Billing, O., Holmgren, Y., Nosek, D., Hedman, H., & Hemmingsson, O. (2021). LRIG1 is a conserved EGFR regulator involved in melanoma development, survival and treatment resistance. Oncogene, 40(21), 3707-3718.

Marqués-Torrejón, M. Á., Williams, C. A., Southgate, B., Alfazema, N., Clements, M. P., Garcia-Diaz, C., ... & Pollard, S. M. (2021). LRIG1 is a gatekeeper to exit from quiescence in adult neural stem cells. Nature communications, 12(1), 2594.

Bakherad, M., Salimi, M., Angaji, S. A., Mahjoubi, F., & Majidizadeh, T. (2021). LRIG1 expression and colorectal cancer prognosis. BMC Medical Genomics, 14, 1-6.

Gao, Y., Liu, C., Zhao, X., Liu, C., Bi, W., & Jia, J. (2021). hsa_circ_0000006 induces tumorigenesis through miR-361-3p targeting immunoglobulin-like domains protein 1 (LRIG1) in osteosarcoma. Annals of Translational Medicine, 9(15).

Li, W., & Zhou, Y. (2019). LRIG1 acts as a critical regulator of melanoma cell invasion, migration, and vasculogenic mimicry upon hypoxia by regulating EGFR/ERK-triggered epithelial–mesenchymal transition. Bioscience Reports, 39(1), BSR20181165.

Li, Q., Liu, B., Chao, H. P., Ji, Y., Lu, Y., Mehmood, R., ... & Tang, D. G. (2019). LRIG1 is a pleiotropic androgen receptor-regulated feedback tumor suppressor in prostate cancer. Nature communications, 10(1), 5494.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols